Homocysteine: When to Order This Test

What Homocysteine Is and Why It Matters

Homocysteine is a sulfur-containing amino acid produced during methionine metabolism. The body recycles it back to methionine through a folate- and B12-dependent pathway, or converts it to cysteine using vitamin B6. When those pathways stall, homocysteine accumulates in the blood.

Elevated plasma homocysteine (hyperhomocysteinemia) has been associated with endothelial dysfunction, oxidative stress, and prothrombotic changes in vascular tissue. A 2002 meta-analysis published in JAMA examined 30 prospective studies and found that each 5 µmol/L increase in homocysteine was associated with a 20% higher risk of coronary heart disease events, independent of traditional risk factors (Homocysteine Studies Collaboration, JAMA 2002). The relationship between homocysteine and atherosclerosis has been studied since Kilmer McCully first proposed the homocysteine theory of vascular disease in 1969.

The test also serves as a functional marker of B-vitamin status. A patient with borderline-low B12 on standard assays might show a normal serum B12 level but a rising homocysteine concentration, revealing tissue-level deficiency before anemia or neuropathy develops (Stabler, NEJM 2013).

Clinical Indications: When to Order the Test

A homocysteine test is not part of routine screening panels. Clinicians order it in specific scenarios where the result will change management.

Unexplained cardiovascular disease in younger patients. A 40-year-old presenting with a first MI or ischemic stroke, particularly without conventional risk factors like diabetes, hypertension, or smoking, warrants homocysteine testing. The American Heart Association has recognized elevated homocysteine as an independent risk factor for atherosclerotic disease (AHA Scientific Statement). Testing becomes especially useful in patients under age 50 with premature coronary artery disease or a family history of early cardiovascular events.

Suspected B12 or folate deficiency. When clinical suspicion exists but serum B12 levels fall in the indeterminate range (200 to 400 pg/mL), homocysteine functions as a second-line confirmatory test. A level above 15 µmol/L in the setting of low-normal B12 supports true deficiency. Methylmalonic acid (MMA) serves a similar confirmatory role but is more specific to B12, while homocysteine rises with deficiency in either folate or B12 (Green et al., Blood 2017).

MTHFR variant evaluation. Patients identified with methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T or A1298C) often request homocysteine testing. The C677T homozygous variant reduces MTHFR enzyme activity by approximately 70%, and roughly 10% to 15% of the U.S. population carries this genotype (Frosst et al., Nat Genet 1995). A normal homocysteine result in an MTHFR-variant carrier is clinically reassuring and often avoids unnecessary supplementation.

Drug-induced elevation monitoring. Certain medications raise homocysteine levels: methotrexate (a folate antagonist), phenytoin, carbamazepine, and nitrous oxide (which inactivates B12). Baseline and periodic homocysteine monitoring may guide supplementation decisions in these patients (Refsum et al., Clin Chem 2004).

Venous thromboembolism workup in younger patients. Mild-to-moderate hyperhomocysteinemia has been associated with a 2- to 4-fold increased risk of venous thrombosis. The Leiden Thrombophilia Study found that homocysteine levels above the 95th percentile carried an adjusted odds ratio of 2.5 for deep vein thrombosis (den Heijer et al., NEJM 1996).

Normal Homocysteine Ranges and How to Interpret Results

The reference range most laboratories report is 5 to 15 µmol/L for fasting plasma homocysteine. Some labs use a tighter upper limit of 12 µmol/L.

Interpretation depends heavily on context. A level of 13 µmol/L in an 80-year-old may reflect age-related renal decline rather than methylation pathology, since homocysteine concentrations increase with age and reduced GFR (Refsum et al., Clin Chem 2004). Men typically run 1 to 2 µmol/L higher than premenopausal women. Postmenopausal women see levels rise toward male ranges.

Severity classification:

| Level (µmol/L) | Classification | Common causes | |---|---|---| | 5 to 15 | Normal | Adequate B-vitamin intake, intact renal function | | 15 to 30 | Mild elevation | B12/folate deficiency, MTHFR variants, renal impairment, medications | | 30 to 100 | Moderate elevation | Severe B-vitamin deficiency, renal failure, combined genetic and nutritional factors | | >100 | Severe elevation | Classical homocystinuria (CBS deficiency), rare |

Fasting samples yield the most reliable results. A non-fasting draw can artificially raise levels by 2 to 4 µmol/L. The sample also needs prompt processing: homocysteine leaks from red blood cells over time, so plasma should be separated within 30 minutes of collection or the blood drawn into a tube containing a stabilizer.

What a High Homocysteine Level Means

A result above 15 µmol/L triggers a diagnostic workup rather than a single diagnosis. The most common cause worldwide is nutritional deficiency of folate, B12, or B6. In populations where grain fortification with folic acid is standard (the United States mandated it in 1998), B12 deficiency has become the predominant nutritional driver of elevated homocysteine.

Chronic kidney disease raises homocysteine through impaired renal clearance. Roughly 85% of patients with end-stage renal disease have hyperhomocysteinemia (Bostom and Lathrop, Kidney Int 1997). Hypothyroidism is another underrecognized cause: thyroid hormone influences hepatic homocysteine metabolism, and TSH normalization often reduces elevated levels.

The clinical significance of mild elevations (15 to 20 µmol/L) remains an area of active investigation. Large randomized trials like HOPE-2 (N=5,522) demonstrated that B-vitamin supplementation reduced homocysteine by 25% but did not significantly reduce the primary composite endpoint of cardiovascular death, MI, or stroke (Lonn et al., NEJM 2006). This finding shifted clinical thinking. Homocysteine may be a marker of cardiovascular risk rather than a direct causal mediator, or the damage from chronic elevation may not be reversible with late-stage supplementation.

A secondary analysis of HOPE-2 did show a 25% reduction in stroke risk with B-vitamin therapy (RR 0.75 to 95% CI 0.59 to 0.97). The VITATOPS trial (N=8,164) found a non-significant 8% reduction in recurrent vascular events among stroke patients receiving B vitamins (VITATOPS Trial Study Group, Lancet Neurol 2010). These mixed results highlight why homocysteine testing is targeted rather than universal.

What a Low Homocysteine Level Means

Low homocysteine (below 5 µmol/L) is rarely clinically concerning and does not carry established disease associations. It can reflect strong methylation capacity, high dietary intake of B vitamins, or supplementation with methylfolate and methylcobalamin.

Some practitioners interpret very low levels (below 4 µmol/L) as a sign of potential overmethylation, but this concept lacks strong evidence from controlled trials. No major medical society has published guidelines defining a clinically actionable lower limit for homocysteine.

How to Lower Homocysteine

The most effective and well-studied approach to reducing elevated homocysteine is B-vitamin supplementation, specifically folate (or 5-methyltetrahydrofolate), vitamin B12, and vitamin B6.

Folate. Supplementation with 400 to 800 mcg daily of folic acid typically reduces homocysteine by 15% to 30%. A Cochrane review of 25 RCTs confirmed that folic acid is the primary driver of homocysteine reduction, with B12 providing a modest additional effect (Marti-Carvajal et al., Cochrane Database Syst Rev 2017). For patients with MTHFR C677T variants, L-methylfolate (the active form) bypasses the enzymatic block.

Vitamin B12. Doses of 500 to 1 to 000 mcg daily of methylcobalamin or cyanocobalamin address the most common nutritional deficiency driving homocysteine elevation in fortified populations. In patients with pernicious anemia or malabsorption, intramuscular or sublingual administration is preferred.

Vitamin B6. Pyridoxine at 25 to 50 mg daily supports the transsulfuration pathway that converts homocysteine to cysteine. It is less effective as monotherapy for lowering homocysteine but adds value in combination with folate and B12.

Dietary approaches. Leafy greens (spinach, kale), legumes, eggs, and organ meats provide the B vitamins required for homocysteine metabolism. The Mediterranean diet pattern, rich in these foods, has been associated with lower homocysteine levels in observational studies (Chrysohoou et al., Am J Clin Nutr 2004).

Address underlying causes. Treating hypothyroidism, adjusting offending medications, or managing renal function may lower homocysteine independently of supplementation. A patient on methotrexate for rheumatoid arthritis, for instance, often benefits from concomitant folic acid 1 mg daily, a practice already recommended by the American College of Rheumatology.

Response to treatment can be assessed by repeating the homocysteine level 6 to 8 weeks after initiating supplementation.

When Homocysteine Testing Is Not Recommended

The United States Preventive Services Task Force (USPSTF) does not recommend routine homocysteine screening in the general adult population for cardiovascular disease prevention (USPSTF, 2009). The American College of Cardiology and American Heart Association 2019 guidelines on primary prevention similarly do not include homocysteine in their recommended risk assessment panel.

Routine testing in asymptomatic individuals without risk factors generates results that rarely change management. The HOPE-2 and NORVIT trials demonstrated that lowering homocysteine with B vitamins in the general high-risk cardiovascular population did not reduce hard clinical endpoints sufficiently to justify screening (Bonaa et al., NEJM 2006).

Testing is best reserved for the specific clinical scenarios outlined above, where the result directly guides a treatment decision.

Ordering the Test: Practical Considerations

Request a fasting plasma homocysteine level. The CPT code is 83090. Most commercial labs and hospital laboratories offer this assay. Ensure the patient has fasted for 8 to 12 hours, since methionine-rich meals transiently raise homocysteine.

Paired testing often adds clinical value. When investigating B-vitamin deficiency, ordering methylmalonic acid (MMA) alongside homocysteine helps distinguish B12 deficiency (both MMA and homocysteine elevated) from folate deficiency (homocysteine elevated, MMA normal). A complete blood count and peripheral smear can identify megaloblastic changes. Serum B12 and folate levels provide direct nutrient measurements.

For cardiovascular risk assessment, homocysteine is most useful as part of an expanded panel that includes high-sensitivity CRP, lipoprotein(a), and an advanced lipid profile. It fills a specific niche: identifying a modifiable, nutrient-responsive contributor to vascular risk that standard panels miss.

Insurance coverage is generally straightforward when the test is ordered with an appropriate ICD-10 code (E72.11 for homocystinuria, R79.89 for other abnormal blood chemistry findings, or the relevant cardiovascular or B-vitamin deficiency code).

Homocysteine in Special Populations

Pregnancy. Elevated homocysteine has been associated with neural tube defects, preeclampsia, and recurrent pregnancy loss. A 2005 meta-analysis in the American Journal of Obstetrics and Gynecology found that women with recurrent early pregnancy loss had significantly higher homocysteine levels than controls (Nelen et al., Obstet Gynecol 2000). Periconceptional folic acid supplementation (400 to 800 mcg daily), already universally recommended, addresses this risk.

Elderly patients. Homocysteine levels rise with age due to declining renal function, reduced B12 absorption (particularly with chronic proton pump inhibitor use), and decreased dietary quality. Levels above 15 µmol/L in older adults have been associated with cognitive decline and dementia risk in observational studies, including the Framingham cohort (Seshadri et al., NEJM 2002). Whether B-vitamin supplementation slows cognitive decline remains unresolved, though the VITACOG trial (N=168) showed that high-dose B vitamins reduced brain atrophy rate by 30% in elderly subjects with elevated homocysteine (Smith et al., PLoS One 2010).

Chronic kidney disease. Homocysteine is almost universally elevated in CKD stage 4 and 5 patients. Standard B-vitamin doses may not normalize levels due to impaired renal clearance. The HOST trial (N=2,056) found no cardiovascular benefit from homocysteine-lowering therapy in advanced CKD patients (Jamison et al., JAMA 2007).

Connecting Homocysteine to the Broader Clinical Picture

Homocysteine testing works best as one piece of a diagnostic puzzle. An isolated elevated result, without clinical context, can lead to unnecessary worry or overtreatment. A result within the normal range does not rule out cardiovascular disease, B12 deficiency with predominantly neurologic manifestations (where MMA is more sensitive), or other metabolic conditions.

The test earns its place in clinical medicine by answering specific questions. Is this patient's borderline B12 causing tissue-level deficiency? Does this young stroke patient have a modifiable metabolic risk factor? Is this MTHFR carrier actually accumulating homocysteine, or is their methylation pathway compensating adequately?

Repeat testing at 6 to 8 weeks after initiating B-vitamin supplementation confirms treatment response. A target below 12 µmol/L is reasonable for most patients, though no randomized trial has established an optimal therapeutic target.